FDA approved belzutifan plus lenvatinib for advanced ccRCC after PD-1/PD-L1 therapy, expanding treatment options for those with disease progression.
|Articles|May 1, 1996
The American Journal of Managed Care
- May 1996
- Volume 2
- Issue 5
Comparison by Systems and Specialties of Medical Outcomes in Patients with Hypertension and Non-Insulin Dependent Diabetes Mellitus
Author(s)Sheldon Greenfield, MD
Advertisement
Articles in this issue
over 30 years ago
Job-Related Stress and the Quality of Pharmacists' Work Lifeover 30 years ago
The Professionalism of Pharmacy in a Managed Care Settingover 30 years ago
Management of the Menopausal Womanover 30 years ago
Any Willing IPA: Shaping the Market Through LegislationAdvertisement
Related to this article
A 3-year registry found dupilumab controlled atopic dermatitis (AD) in most children, though those under 6 years were likelier to stop treatment.
Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Boarding admitted patients on inpatient floor hallways can alleviate emergency department (ED) crowding. Outcomes tend to be positive, but the published evidence is weak, according to this systematic review.
Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.
Most community oncology practices now administer bispecific antibodies in-office, but reimbursement gaps remain a top barrier, a survey finds.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Advertisement
Advertisement
Trending on AJMC
1
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
2
Surrogate End Points, Drug Costs Complicate Oncology Formularies
3
Oncology Patients in Clinical Trials: A Health Care Cost Analysis
4
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
5